AACR Annual Meeting 2025, Chicago, IL, April 25-30

Conference

genOway presentation

Event
-
April 25, 2025

genOway’s program at the American Association for Cancer Research Annual Meeting 2025

🔬 Spotlight Theater presentation

Tuesday, April 29, 2025 | 3 pm - Spotlight Theater E

Title: "Assessment of translational tumor biology, and biologic's efficacy and safety in preclinical humanized models"

Presenter: Kader Thiam, CSO & SVP – Discovery, Preclinical Models & Services

Presentation highlights:

  • genO-BRGSF-HIS mouse is a tool to assess the efficacy and safety of immunotherapies targeting lymphoid and myeloid cellsgenO-BRGSF-HIS mouse
  • TME in genO-BRGSF-HIS mice is shaped by tumor type and tumor burden
  • genO-hFcγR model represents an alternative to genO-BRGSF-HIS to evaluate compounds working through Fc-mediated functions


📰 Poster presentations


Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice | Download poster here

  • Human CD47 and SIRPα expression patterns recapitulate the murine expression of CD47 and SIRPα in genO-hCD47/hSIRPα model
  • Efficacy and safety of CD47- and/or SIRPα-targeting agents can be assessed in the genO-hCD47/hSIRPα model
  • genO-hCD47/hSIRPα model is suitable for biodistribution assay for non-invasive in vivo imaging of tumors


Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies | Download poster here

  • genO-BRGSF-HIS mouse is permissive to cell line xenograft engraftment
  • TME composition and cell polarization evolve with tumor burden and depend on tumor type in genO-BRGSF-HIS mouse
  • genO-BRGSF-HIS mouse model is a valuable tool to investigate mechanism of action of immunotherapies


Functional γδ T cells in genO-BRGSF-HIS mice | Download poster here

  • γδ T cells develop in genO-BRGSF-HIS mice and can be expanded ex vivo and in vivo using Vγ9 expanders
  • γδ T cells are recruited into the TME of tumor-bearing genO-BRGSF-HIS mice
  • genO-BRGSF-HIS model brings a new perspective to evaluate therapies designed to expand and activate γδ T cells


genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies | Download poster here

  • Humanization of both CCR8 and CCL1 is required for a functional axis and does not alter immune cell distribution in genO-hCCR8/hCCL1 compared to WT mice
  • CCR8-targeting therapies can be assessed in genO-hCCR8/hCCL1 model
  • Human-like expression pattern of CCR8 in genO-BRGSF-HIS naïve Tregs makes it a more suitable model for safety and PD assessment

AACR Annual Meeting 2025, Chicago, IL, April 25-30

Get in touch

Let us know how we can help

Other news & events

AACR Annual Meeting 2025, Chicago, IL, April 25-30
Conference
genOway presentation
Event
-
Apr 2025
Read on
Tumour Models Nordics, Stockholm, Sweden, April 9-10, 2025
Conference
Event
-
Apr 2025
Read on
7th Treg-Directed Therapies Summit 2025, Boston, MA, March 25-27, 2025
Conference
Event
-
Mar 2025
Read on
NextGen Biomed 2025, London, UK, March 12-14, 2025
Conference
Event
-
Feb 2025
Read on
genOway signs a three-year contract with a global philanthropic organization supporting the development of infectious diseases therapies
Partnership
News
-
Feb 2025
Read on